Betamethasone Valerate
(Synonyms: 倍他米松戊酸酯,Betamethasone 17-valerate) 目录号 : GC13638A glucocorticoid with anti-inflammatory activity
Cas No.:2152-44-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Betamethasone valerate (BV or BET), also called betamethasone 17-valerate [2], is a commonly used anti-inflammatory corticosteroid, used to manufacture dermatological drug products for topical applications [3] [1]. Its IC50 in normal rats is 3.4±0.5 nM [4]. BV can reduce glucose-6-phosphate dehydrogenase (G-6-PDH) activity in vitro [5].
G-6-PDH (EC.1.1.1.49) is an enzyme that catalyzes the first step in the pentosephosphate pathway [6].
The presence of BV at a concentration of 4.6 mM/l provoked a still further diminuition of the G-6-PDH-activity of human skin homogenates that followed the incubation for 120 min at 37°C in media containing 5% dimethylformamide and in which the concentration of G-6-PDH changed from about 55 mU/ml to 9 mU/ml [5].
Compared with sodium cromoglycate (SCG, 80mg daily), treatment of betamethasone valerate (BV, 800μg daily) for 4 weeks made children requiring bronchodilators for perennial asthma significantly require less bronchodilator drugs, and have fewer symptoms and higher daily peak expiratory flow rates [7]. Compared with coal tar (10% LCD) cream, after a 2 week wash-out period, treatment with betamethasone valerate cream (0.1%) twice daily for 6 weeks made patients with stable, mild-moderate plaque psoriasis get more mean reduction of PASI score from baseline. The final effect of betamethasone valerate was significantly greater clearance and improvement [8].
References:
[1]. Hayam Mahmoud Lotfy, Hesham Salem, Mohammad Abdelkawy, et al. Spectrophotometric methods for simultaneous determination of betamethasone valerate and fusidic acid in their binary mixture. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2015, 140: 294-304.
[2]. J. Hywel Jones, M. Atkinson, A. Morton Gill, et al. Betamethasone 17-Valerate and Prednisolone 21-Phosphate Retention Enemata in Proctocolitis. British Medical Journal, 1971, 3: 84-86.
[3]. Jayalakshmi Somuramasami, Yu-Chien Wei, Emad F. Soliman, et al. Static headspace gas chromatographic method for the determination of low and high boiling residual solvents in Betamethasone valerate. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54: 242-247.
[4]. Makoto Muramatsu, Makoto Tanaka, Susumu Otomo, et al. Characteristics of Binding of a New Anti-Inflammatory Glucocorticoid, Hydrocortisone 17-Butyrate 21-Propionate (HBP), to Glucocorticoid Receptors of Rat liver. Japan. J. Pharmacol., 1985, 37: 143-150.
[5]. W. P. Raab and B. M. Gmeiner. Inhibition of Glucose-6-Phosphate Dehydrogenase Activity by Betamethasone and Three of its Esters with Dermatological Importance. Arch. Derm. ges., 1975, 253: 113-118.
[6]. Mohamed Amara Camara, Miaomiao Tian, Liping Guo, et al. Application of capillary enzyme micro-reactor in enzyme activity and inhibitors studies of glucose-6-phosphate dehydrogenase. J. Chromatogr. B, 2015, 990: 174-180.
[7]. S. H. Ng, C. H. Dash and Suzanne J. Savage. Betamethasone valerate compared with sodium cromoglycate in asthmatic children. Postgraduate Medical Journal, 1977, 53: 315-320.
[8]. Prasutr Thawornchaisit and Kitiphong Harncharoen. A Comparative Study of Tar and Betamethasone Valerate in Chronic Plaque Psoriasis: A Study in Thailand. J Med Assoc Thai, 2007, 90 (10): 1997-2002.
Cas No. | 2152-44-5 | SDF | |
别名 | 倍他米松戊酸酯,Betamethasone 17-valerate | ||
化学名 | [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate | ||
Canonical SMILES | CCCCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CO | ||
分子式 | C27H37FO6 | 分子量 | 476.58 |
溶解度 | ≥ 19.2mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0983 mL | 10.4914 mL | 20.9828 mL |
5 mM | 0.4197 mL | 2.0983 mL | 4.1966 mL |
10 mM | 0.2098 mL | 1.0491 mL | 2.0983 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。